10-K: FOXO Technologies Inc. Navigates Strategic Shift Amidst Financial Challenges

FOXO Technologies Inc. is exploring strategic alternatives, including a potential merger, while focusing on its Bioinformatics Services and AI-driven health solutions due to financial constraints.

Summary

• FOXO Technologies Inc., a company focused on commercializing scientific discoveries in health and longevity, is undergoing a strategic shift.
• The company is exploring strategic alternatives, including a potential merger or sale of assets, while focusing on consumer-facing AI technology and its Bioinformatics Services.
• FOXO has paused sales of its life insurance products and is redeveloping its Longevity Report due to financial constraints.
• The company has a history of losses, with accumulated deficits of $177,060,000 as of December 31, 2023, and a net loss of $29,829,000 for the year ended December 31, 2023.
• The company's independent auditor has raised substantial doubt about its ability to continue as a going concern.
• FOXO Labs, one of the company's two segments, is focused on research and development and commercializing epigenetic biomarker technology.
• The company's Bioinformatics Services, which provides data processing and analysis, is now a primary offering.
• The company has reduced its headcount and expenses to conserve cash resources.
• The company has received notices of allowance for two patents related to machine learning techniques for epigenetic biomarkers.
• The company's cash position is expected to fund operations only through the third quarter of 2024, requiring additional capital or a strategic transaction.

Sentiment

Score: 3

Explanation: The document presents a company facing significant financial challenges and strategic uncertainty. While there are some positive aspects, such as the focus on Bioinformatics Services and AI, the overall sentiment is negative due to the going concern warning, history of losses, and need for additional capital.

Positives

• The company is shifting its focus to its Bioinformatics Services, which has the potential to generate revenue and accelerate new discoveries in epigenetics.
• The company has a unique dataset of health and epigenetic data from over 1,000 individuals, which can be used to develop new products and services.
• The company has received notices of allowance for two patents related to machine learning techniques for epigenetic biomarkers.
• The company is exploring strategic alternatives, including a potential merger, which could provide additional value to stockholders.
• The company is leveraging its expertise in epigenetics, machine learning, and bioinformatics to develop new products and services.

Negatives

• The company has a history of losses and may not achieve or maintain profitability in the future.
• The company's independent auditor has included an explanatory paragraph relating to its ability to continue as a going concern.
• The company does not have adequate cash resources to fund its operations beyond the third quarter of 2024.
• The company has paused sales of its life insurance products and is redeveloping its Longevity Report.
• The company has experienced recent management changes, including the departure of its former Interim Chief Executive Officer and Chief Science Officer.
• The company is in default of a settlement agreement with Smithline due to the failure to pay $300,000 by December 31, 2023.
• The company is in default of its Senior PIK Notes.

Risks

• The company may not be successful in identifying or completing any strategic alternative, including a merger or acquisition.
• The company may not be able to raise additional capital on terms acceptable to it or at all.
• The company may be forced to delay, reduce, or eliminate its commercialization efforts or cease all operations if it is unable to secure additional funding.
• The company's business is subject to numerous risks and uncertainties, including competition, regulatory changes, and intellectual property challenges.
• The company's ability to establish and grow its epigenetic testing services depends on developing epigenetic biomarkers that attract customers.
• The company relies on a limited number of third-party suppliers for its epigenetic testing services.
• The company may be subject to claims that its employees have wrongfully used or disclosed confidential information of third parties.
• The public market for the company's securities is volatile, which may affect the ability of investors to sell their securities.
• The company is subject to the continued listing standards of the NYSE American, and failure to satisfy these criteria may result in delisting of its Class A Common Stock.

Future Outlook

The company intends to leverage its epigenetic data and expertise to develop new products and services, including a potential AI platform for health and wellness. The company also intends to continue building strategic alliances with new partners in academia, business, healthcare, and government. The company will continue to evaluate and develop commercialization opportunities for its product and service offerings and research findings.

Management Comments

• The company believes there is value in what epigenetic biomarkers will be able to provide to the world.
• The company believes it is well-positioned to help reduce barriers in advancing epigenetic research and the development of epigenetic-based products.
• The company believes that its versatile datasets allow it to use epigenetics to examine one's past behaviors/traits and future disease risk.
• The company believes that its proprietary data allows it to quickly assess new measures and biomarkers that can be measured in biospecimens and relate those biomarkers to epigenetic data and other health metrics.

Industry Context

The company's strategic shift towards AI-driven health solutions and Bioinformatics Services reflects a growing trend in the healthcare industry towards personalized medicine and data-driven insights. The company's focus on epigenetics aligns with the increasing interest in this field as a tool for understanding and addressing health and longevity.

Comparison to Industry Standards

• The company's focus on epigenetics is a relatively new area in the health and wellness testing market, making direct comparisons to established companies difficult.
• Companies like 23andMe and AncestryDNA offer genetic testing services, but FOXO's focus on epigenetics and its Bioinformatics Services differentiates it from these competitors.
• The company's financial performance is significantly below industry standards for established companies, reflecting its development stage and financial challenges.
• The company's reliance on third-party suppliers for its epigenetic testing services is a common practice in the industry, but it also presents a risk to its operations.
• The company's exploration of strategic alternatives, including a potential merger, is a common strategy for companies facing financial challenges in the biotechnology sector.

Management Changes

Legal Proceedings

• The company is in default of a settlement agreement with Smithline due to the failure to pay $300,000 by December 31, 2023.
• The company is currently in negotiations with Smithline on a resolution.
• The company is in default of its Senior PIK Notes.

Related Party Transactions

• The company has entered into a letter agreement and a master software and services agreement with KR8 AI, a company in which the company's Interim CEO and Interim CFO are substantial shareholders.
• The company has obtained loans from Andrew J. Poole, a former director of the company.
• The company has entered into a consulting agreement with Bespoke Growth Partners, Inc., a company controlled by a former shareholder.
• The company has entered into a Shares for Services Agreement with Mitchell Silberberg & Knupp LLP, a service provider.
• The company has entered into a Shares for Services Agreement with Joseph Gunnar & Co., LLC, a service provider.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial challenges and the potential for delisting.
• Employees have been impacted by layoffs and may face further job insecurity.
• Customers may experience delays or changes in the company's products and services.
• Suppliers may face uncertainty regarding future contracts and payments.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company will continue to explore strategic alternatives, including a potential merger or sale of assets.
• The company will focus on developing and commercializing its Bioinformatics Services.
• The company will continue to develop its AI-driven health solutions.
• The company will seek additional capital through equity or debt financings.
• The company will work to regain compliance with NYSE American listing standards.

Key Dates

Keywords

epigenetics, bioinformatics, AI, machine learning, health, longevity, strategic alternatives, merger, acquisition, life insurance, biomarkers, financial, capital, research, development